Randomized trial of androgen deprivation therapy (ADT) + enzalutamide (Arm A) versus ADT + bicalutamide (Arm B) in metastatic hormone sensitive prostate cancer (mHSPC)
Year: 2018
Type: article
Study design: Clinical Trial
Abstract: Background: The addition of abiraterone or docetaxel has shown overall survival (OS) benefit in mHSPC. There is adequate rationale for clinical efficacy of enzalutamide and ADT combination in mHSPC. We compared the combination of enzalutamide (Arm A) or bicalutamide (Arm B), each with ADT in mHSPC.
Source: Annals of Oncology
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $5,080
OpenAlex ID: W2898219316